The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifical...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral t...
Headway, the company building a new mental healthcare system, announced its participation in the Aligned Innovation initiative, a groundbreaking cross-indu...
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New ...
Theriva™ Biologics (NYSE American: TOVX), a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and relate...
Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, control...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4), for Alzhei...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates announced a significant expansion in their quality control (QC) test...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ta...
Merck, a leading science and technology company, announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconju...
AbbVie (NYSE: ABBV) and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing...
Bristol Myers Squibb (NYSE: BMY) announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio...
© 2025 Biopharma Boardroom. All Rights Reserved.
